HC Wainwright & Co. reiterates Buy rating on Zentalis Pharmaceuticals, $10 price target
HC Wainwright & Co. reiterated a Buy rating on Zentalis Pharmaceuticals with a $10 price target, implying a 369.5% upside from the Oct 16 close of $2.13. The company reported encouraging survival data for azenosertib, showing a median OS of 15.8 months in Cyclin E1-positive patients, and improved treatment management in ongoing trials.
How this was made
The 30-second read
Why it matters
Analyst upgrade may trigger short‑term buying interest and set a new price ceiling.
Market read
New clinical data and analyst upgrade provide fresh upside potential for Zentalis.
What to watch
Potential competition from other Cyclin E1‑targeted agents and reimbursement uncertainties.
Background
Analyst note from HC Wainwright highlighting new trial results and raising the price target.
Ticker impact
HC Wainwright reiterated a Buy rating on Zentalis and set a $10 price target after reporting new interim overall survival data from the DENALI trial.
likely upward pressure as the market prices in the improved outlook and $10 target.
The new survival data and reduced discontinuation rates suggest clinical progress, prompting the analyst to raise expectations.
Market effects
Positive data may lift sentiment for the broader oncology biotech sector.
Limited to U.S. biotech investors.
Modest, primarily affecting investors tracking early‑stage cancer therapeutics.
Counterpoint
The trial data are interim; outcomes could change in later phases, making the $10 target optimistic.
Key entities
- companyZentalis Pharmaceuticals
Biotech firm developing azenosertib for Cyclin E1‑positive cancers.
- analystHC Wainwright & Co.
Equity research firm that issued the Buy rating and $10 target.